Trial Profile
A Phase 1, Open-Label, 3-Period Crossover Study Of The Effect Of An Antacid, A Proton Pump Inhibitor And An H2-Receptor Antagonist On Palbociclib (PD-0332991) Bioavailability Under Fed Conditions In Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 May 2017
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Famotidine; Rabeprazole; Simethicone
- Indications Breast cancer; Colorectal cancer; Glioblastoma; Liposarcoma; Mantle-cell lymphoma; Multiple myeloma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 18 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov
- 02 Apr 2014 New trial record